0 CHECKOUT

Malignant Pleural Mesothelioma - Pipeline Review, H1 2015

  • ID: 3293061
  • May 2015
  • 199 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Aduro BioTech, Inc.
  • Biogen, Inc.
  • CanBas Co., Ltd.
  • GlaxoSmithKline plc
  • MolMed S.p.A.
  • Pfizer Inc.
  • MORE

Malignant Pleural Mesothelioma - Pipeline Review, H1 2015

Summary

This, ‘Malignant Pleural Mesothelioma - Pipeline Review, H1 2015’, provides an overview of the Malignant Pleural Mesothelioma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Malignant Pleural Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Pleural Mesothelioma and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Aduro BioTech, Inc.
  • Biogen, Inc.
  • CanBas Co., Ltd.
  • GlaxoSmithKline plc
  • MolMed S.p.A.
  • Pfizer Inc.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Malignant Pleural Mesothelioma Overview
Therapeutics Development
Pipeline Products for Malignant Pleural Mesothelioma - Overview
Pipeline Products for Malignant Pleural Mesothelioma - Comparative Analysis
Malignant Pleural Mesothelioma - Therapeutics under Development by Companies
Malignant Pleural Mesothelioma - Therapeutics under Investigation by Universities/Institutes
Malignant Pleural Mesothelioma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Malignant Pleural Mesothelioma - Products under Development by Companies
Malignant Pleural Mesothelioma - Products under Investigation by Universities/Institutes
Malignant Pleural Mesothelioma - Companies Involved in Therapeutics Development
Aduro BioTech, Inc.
Advantagene, Inc.
Amphera BV
Bayer AG
Biogen, Inc.
Bionomics Limited
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
CanBas Co., Ltd.
Concordia Healthcare Corp.
EnGeneIC Ltd
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
Genelux Corporation
GlaxoSmithKline plc
Juno Therapeutics Inc.
MedImmune, LLC
Merck & Co., Inc.
MolMed S.p.A.
Morphotek, Inc.
Novartis AG
Oxford BioMedica plc
Pfizer Inc.
Pharma Mar, S.A.
Polaris Pharmaceuticals, Inc.
Synta Pharmaceuticals Corp.
Verastem, Inc.
Virttu Biologics Limited
Malignant Pleural Mesothelioma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
amatuximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
anetumab ravtansine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ascrinvacumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BG-00001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-986148 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BNC-105 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CBP-501 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy 1 for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CRS-207 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
defactinib hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FP-1039 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ganetespib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for Malignant Pleural Mesothelioma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GLONC-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-2256098 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HSV-1716 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
iCasp9M28z - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JTCR-016 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MesoCancerVac - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MesoCART - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody Conjugated to Target Mesothelin for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
napabucasin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NGR-hTNF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nintedanib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pegargiminase - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pembrolizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
porfimer sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RG-7787 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Mestatic Lung Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TargomiRs - Drug Profile
Product Description
Mechanism of Action
R&D Progress
trabectedin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tremelimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TroVax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine For Oncolytic Newcastle Disease Virus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VS-5584 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Malignant Pleural Mesothelioma - Recent Pipeline Updates
Malignant Pleural Mesothelioma - Dormant Projects
Malignant Pleural Mesothelioma - Discontinued Products
Malignant Pleural Mesothelioma - Product Development Milestones
Featured News & Press Releases
May 14, 2015: PharmaMar announces new advances in oncology at ASCO 2015 for its compound YONDELIS in small cell lung cancer, soft tissue sarcoma, and mesothelioma
Apr 23, 2015: Mesothelioma Immunotherapy Vaccine Receives Orphan Drug Designation from FDA, Baron & Budd Reports
Apr 19, 2015: Early Findings with KEYTRUDA (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting
Apr 19, 2015: Immunotherapy drug pembrolizumab shows promise for mesothelioma patients
Mar 26, 2015: Aduro Receives Orphan Drug Designation for CRS-207 in Mesothelioma
Mar 18, 2015: New Data Investigating Merck’s KEYTRUDA (pembrolizumab) in Advanced Non-Small Cell Lung Cancer and Mesothelioma to Be Presented in Clinical Trials Plenary Session at AACR 2015
Jan 20, 2015: Verastem Doses First Patient In Phase 1 Clinical Trial Evaluating VS-5584 In Combination With VS-6063 In Mesothelioma
Jan 20, 2015: Verastem Receives Orphan Medicinal Product Designation from the European Commission for VS-5584 in Mesothelioma
Dec 18, 2014: Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Receives Orphan Drug Designation in the United States and the European Union for the Treatment of Malignant Pleural Mesothelioma
Oct 24, 2014: Verastem Presents New Data on Mesothelioma Programs at the 12th International Mesothelioma Interest Group Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Malignant Pleural Mesothelioma, H1 2015
Number of Products under Development for Malignant Pleural Mesothelioma - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015
Malignant Pleural Mesothelioma - Pipeline by Aduro BioTech, Inc., H1 2015
Malignant Pleural Mesothelioma - Pipeline by Advantagene, Inc., H1 2015
Malignant Pleural Mesothelioma - Pipeline by Amphera BV, H1 2015
Malignant Pleural Mesothelioma - Pipeline by Bayer AG, H1 2015
Malignant Pleural Mesothelioma - Pipeline by Biogen, Inc., H1 2015
Malignant Pleural Mesothelioma - Pipeline by Bionomics Limited, H1 2015
Malignant Pleural Mesothelioma - Pipeline by Boehringer Ingelheim GmbH, H1 2015
Malignant Pleural Mesothelioma - Pipeline by Boston Biomedical, Inc., H1 2015
Malignant Pleural Mesothelioma - Pipeline by Bristol-Myers Squibb Company, H1 2015
Malignant Pleural Mesothelioma - Pipeline by CanBas Co., Ltd., H1 2015
Malignant Pleural Mesothelioma - Pipeline by Concordia Healthcare Corp., H1 2015
Malignant Pleural Mesothelioma - Pipeline by EnGeneIC Ltd, H1 2015
Malignant Pleural Mesothelioma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Malignant Pleural Mesothelioma - Pipeline by Five Prime Therapeutics, Inc., H1 2015
Malignant Pleural Mesothelioma - Pipeline by Genelux Corporation, H1 2015
Malignant Pleural Mesothelioma - Pipeline by GlaxoSmithKline plc, H1 2015
Malignant Pleural Mesothelioma - Pipeline by Juno Therapeutics Inc., H1 2015
Malignant Pleural Mesothelioma - Pipeline by MedImmune, LLC, H1 2015
Malignant Pleural Mesothelioma - Pipeline by Merck & Co., Inc., H1 2015
Malignant Pleural Mesothelioma - Pipeline by MolMed S.p.A., H1 2015
Malignant Pleural Mesothelioma - Pipeline by Morphotek, Inc., H1 2015
Malignant Pleural Mesothelioma - Pipeline by Novartis AG, H1 2015
Malignant Pleural Mesothelioma - Pipeline by Oxford BioMedica plc, H1 2015
Malignant Pleural Mesothelioma - Pipeline by Pfizer Inc., H1 2015
Malignant Pleural Mesothelioma - Pipeline by Pharma Mar, S.A., H1 2015
Malignant Pleural Mesothelioma - Pipeline by Polaris Pharmaceuticals, Inc., H1 2015
Malignant Pleural Mesothelioma - Pipeline by Synta Pharmaceuticals Corp., H1 2015
Malignant Pleural Mesothelioma - Pipeline by Verastem, Inc., H1 2015
Malignant Pleural Mesothelioma - Pipeline by Virttu Biologics Limited, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Malignant Pleural Mesothelioma Therapeutics - Recent Pipeline Updates, H1 2015
Malignant Pleural Mesothelioma - Dormant Projects, H1 2015
Malignant Pleural Mesothelioma - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Malignant Pleural Mesothelioma, H1 2015
Number of Products under Development for Malignant Pleural Mesothelioma - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Aduro BioTech, Inc.
Advantagene, Inc.
Amphera BV
Bayer AG
Biogen, Inc.
Bionomics Limited
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
CanBas Co., Ltd.
Concordia Healthcare Corp.
EnGeneIC Ltd
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
Genelux Corporation
GlaxoSmithKline plc
Juno Therapeutics Inc.
MedImmune, LLC
Merck & Co., Inc.
MolMed S.p.A.
Morphotek, Inc.
Novartis AG
Oxford BioMedica plc
Pfizer Inc.
Pharma Mar, S.A.
Polaris Pharmaceuticals, Inc.
Synta Pharmaceuticals Corp.
Verastem, Inc.
Virttu Biologics Limited

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Photocure ASA
  • Roche Diagnostics Ltd.
  • Abbott Laboratories Ltd.
  • Pfizer Inc.
  • Novartis AG
  • Becton, Dickinson and Company (BD)